The offer of total issue size of Up to 14,100,000 Equity Shares of face value of Rs10 comprises of a fresh issue of Up to 5,000,000 Equity Shares and an Offer for sale of Up to 9,100,000 Equity Shares.
FinTech BizNews Service
Mumbai, 5 January 2026: Hindustan Laboratories Limited an Indian pharmaceutical company primarily engaged in the large-scale manufacturing and supply of generic medicines to government institutions under a business-to-government (B2G) framework has filed DRHP with SEBI for its proposed IPO.
Rajesh Vasantray Doshi, Kunjal C. Dedhia And Krishiv Rajesh Doshi are the promoters of the company.
The offer of total issue size of Up to 14,100,000 Equity Shares of face value of Rs10 comprises of a fresh issue of Up to 5,000,000 Equity Shares and an Offer for sale of Up to 9,100,000 Equity Shares.
The company proposes to utilize the Net Proceeds towards, Funding the working capital requirements; and general corporate purposes.
Hindustan Laboratories Limited is an Indian pharmaceutical company primarily engaged in the large-scale manufacturing and supply of generic medicines to government institutions under a business-to-government (B2G) framework. Its products are primarily generic formulations which are medicines for which the patents have expired and that are typically used as a substitute for other expensive branded medicines. The company supply its products primarily under procurement contracts for central government projects under the Ministry of Health and Family Welfare through GoI agencies as well as state government agencies or bodies (together, “Government Customers”). The products are supplied either under brand names or under their generic names, depending on the specific requirements and preferences of its customers. Regardless of the nomenclature, all the products (save for those the company manufacture for others) carry its logo, ensuring consistent brand identity and quality assurance. The company supplied its products across India to 27 States and Union Territories during the six months ended September 30, 2025, and to 27 states and Union Territories during Fiscal 2025.
Its product portfolio encompasses a diverse range of therapeutic segments catering to both acute and chronic healthcare needs. These include anti-allergic, anti-diabetic, anti-infectives, anti-malarial, antiparasitic, blood related, cardiac, gastro-intestinal, keratolytic. nutritional and mineral supplements, pain and analgesics, respiratory nutritional and mineral supplements and vitamin supplements.
The Equity Shares, offered through the Red Herring Prospectus are proposed to be listed on the Stock Exchanges, being BSE Limited (“BSE”) and National Stock Exchange of India Limited (“NSE”) (NSE, together with BSE, the “Stock Exchanges”).
Choice Capital Advisors Private Limited is the book running lead manager to the issue.
